Business Wire

NM-SCEYE

15.6.2022 16:53:08 CEST | Business Wire | Press release

Share
Sceye HAPS Ascend to Stratosphere Using Renewable Energy Sources

Sceye, a manufacturer of High-Altitude Platform Stations (HAPS), announced today that it reached the stratosphere with the aim of demonstrating the ability to stay over an area of operation for months at a time using renewable energy sources. The milestone test launch, which is using patented solar and battery power, puts Sceye on track to expand internet access to remote populations, monitor greenhouse gasses down to individual emitters, and detect natural disasters as they begin. The company also announced additional test flights for Q3 and Q4 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614006039/en/

Sceye’s HAPS launched at 6:55 AM MDT from the company’s hangar at the Roswell International Airport.

“Today’s test flight holds extraordinary potential for stratospheric discovery,” said Sceye founder and CEO, Mikkel Vestergaard Frandsen. “By maintaining position in the stratosphere for extended periods of time, we can begin realizing the promises of the stratosphere for life on Earth. Universal internet access, methane monitoring, and wildfire detection are all at our fingertips.”

Today’s launch objectives were to:

  • Test durability and performance of renewable power systems in the stratosphere
  • Demonstrate the ability to stay over an area of operation
  • Maintain a constant float altitude in the stratosphere

Sceye’s HAPS design, in the form of an enhanced balloon, can lift a variety of payloads for connectivity, earth observation, and scientific research. Its hull fabric can manage the extreme environment of the stratosphere, and optimizes strength, helium retention, and thermal management. High-performance batteries and solar panels close the power loop: enough power storage to last until sunrise, and efficient solar cells to collect energy during the day.

“We are thrilled to see years of research and development culminating in this milestone moment,” said David Kim, Sceye’s Chief Technology Officer. “It is the very best application of material science pushing the boundaries of near space.”

Chief of Mission Operations, Stephanie Luongo, said, “This launch is the second of six in our test program this year intended to verify payload and automated flight while ensuring safe operations. We’re excited to learn more from upcoming flight tests planned for late summer and fall.”

In October 2021, Sceye was the first to connect a Massive MIMO antenna with 3D beamforming from the stratosphere directly to smartphones on the ground over a 140 km distance — a world record in Open RAN. In March 2022, Sceye successfully validated its automated flight software which increases the reliability of its HAPS during its most critical phases of flight – launch and ascent.

Sceye has partnered with the U.S. Environmental Protection Agency (EPA), New Mexico Economic Development Department, and New Mexico Environment Department on a five-year study to monitor air quality in the State of New Mexico. Sceye’s HAPS will track methane emissions with a sub 1-m resolution, allowing them to determine pollution levels as well as pinpoint individual emitters.

About Sceye

Sceye is a material science company founded in 2014 to unleash the possibilities in the stratosphere by uplifting and connecting all people, and protecting our planet. The company has developed a new generation of stratospheric platforms to provide universal and equitable connectivity, improve climate change monitoring, natural resource stewardship, forest fire monitoring and better detect and contain disasters before they spiral out of control.

Sceye continues the humanitarian work of founder and CEO Mikkel Vestergaard Frandsen. As owner and former CEO of the public health companies Vestergaard and LifeStraw, he led innovations in material science that have saved millions of lives. LifeStraw water filters have helped nearly eradicate Guinea worm disease, and PermaNet, bed nets made from innovative fibers that release microscopic doses of insecticide, have helped reduce global malaria deaths by more than half.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit

Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release

Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye